The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $511.08

Today's change+4.57 +0.90%
Updated July 2 4:00 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $511.08

Today's change+4.57 +0.90%
Updated July 2 4:00 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc up (U.S.)$4.57

Regeneron Pharmaceuticals Inc closed up Thursday by (U.S.)$4.57 or 0.90% to (U.S.)$511.08. Shares have lost 1.83% over the last five days, but have gained 24.58% over the last year to date. This security has outperformed the S&P 500 by 59.65% during the last year.

Key company metrics

  • Open(U.S.) $509.50
  • Previous close(U.S.) $506.51
  • High(U.S.) $512.50
  • Low(U.S.) $505.29
  • Bid / Ask-- / --
  • YTD % change+24.58%
  • Volume374,932
  • Average volume (10-day)523,545
  • Average volume (1-month)784,189
  • Average volume (3-month)752,534
  • 52-week range(U.S.) $295.76 to (U.S.) $544.00
  • Beta0.89
  • Trailing P/E162.09×
  • P/E 1 year forward45.75×
  • Forward PEG2.29×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.15
Updated July 2 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.71%

Based on its net profit margin of 11.71%, Regeneron Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.30%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue870802726666
Total other revenue--------
Total revenue870802726666
Gross profit786743670619
Total cost of revenue84595646
Total operating expense587578543454
Selling / general / administrative159144150102
Research & development343352338295
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)123011
Other operating expenses, total--------
Operating income283225183212
Interest income (expense), net non-operating-6-6-9-10
Gain (loss) on sale of assets--------
Other--------
Income before tax277221176203
Income after tax761108093
Income tax, total20111196110
Net income761108093
Total adjustments to net income--------
Net income before extra. items761108093
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items761108093
Inc. avail. to common incl. extra. items761108093
Diluted net income761108393
Dilution adjustment--030
Diluted weighted average shares115114117113
Diluted EPS excluding extraordinary itemsvalue per share0.660.970.700.82
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.671.070.700.86